Key Takeaway: Nurix is focused on developing breakthrough therapies by translating novel scientific insights. The company emphasizes its multi-modal portfolio of wholly owned and partnered assets aimed at combating cancer and autoimmune diseases. The article highlights their commitment to protein degradation resources.
Price reaction · baseline $14.51 (2024-04-02T16:18:00.000Z) · hit during market hours · 2 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
+2.4%
Market Sentiment Analysis
POSITIVE FACTORS
Focus on translating scientific insights into therapies.
Advancement of a multi-modal portfolio.
Commitment to addressing cancer and autoimmune diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is Nurix focused on?
Nurix is dedicated to developing breakthrough therapies for cancer and autoimmune diseases.
What resources does Nurix provide?
Nurix offers protein degradation resources as part of their research efforts.
What is the goal of Nurix's portfolio?
The goal is to advance a multi-modal portfolio of wholly owned and partnered assets.